Skip to content
Oral Solution Allopathic

Supotaria 1 gm/5 ml oral solution

Generic: Glycopyrronium Bromide (Injection)

Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength1 gm/5 ml
PackOne bottle

Reviewed by: not listed yet. Source: not listed yet.

Last updated December 11, 2025.

Compare

Same generic, same strength

Sorted by price per oral solution. Ask your pharmacist before you switch brands.

Glycopyrronium Bromide (Injection) 1 gm/5 ml oral solutions

Prices as listed on BestinMeds.

1 brand listed
Supotaria, 100.00 ml (this medicine)5.00 taka per oral solution

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Glycopyrronium Bromide (Injection) guide

Indications

Reverse residual neuromuscular blockade In Anesthesia: As a pre-operative antimuscarinic agent to reduce salivary, tracheobronchial and pharyngeal sections and to reduce the acidity of the gastric contents. As a pre-operative or intra-operative antimuscarinic to attenuate or prevent intra-operative bradycardia with the use of suxamethonium or due to cardiac vagal reflexes. ... Read more In Anesthesia: As a pre-operative antimuscarinic agent to reduce salivary, tracheobronchial and pharyngeal sections and to reduce the acidity of the gastric contents. As a pre-operative or intra-operative antimuscarinic to attenuate or prevent intra-operative bradycardia with the use of suxamethonium or due to cardiac vagal reflexes. To protect against the peripheral muscarinic actions of anticholinesterases such as neostigmine and pyridostigmine, used to reverse residual neuromuscular blockade produced by non-depolarizing muscle relaxants. In Peptic Ulcer: For use in adults as adjunctive therapy for the treatment of a peptic ulcer when the rapid anticholinergic effect is desired or when oral medication is not tolerated.

Dosage and administration

Pre-anesthetic Use: Adults: 0.2 mg to 0.4 mg intravenously or intramuscularly before the induction of anesthesia. Alternatively, a dose of 0.004 to 0.005 mg/kg up to a maximum of 0.4 mg may be used. Larger doses may result in profound and prolonged antisialogogue effect, which may be unpleasant for the patient. Children (1 month to 12 years of age): 0.004 to 0.008 mg/kg up to a maximum of 0.2 mg intravenously or intramuscularly before the induction of anesthesia. Larger doses may result in profound and prolonged antisialogogue effect which may be unpleasant for the patient. Intraoperative Use: When used to treat arrhythmias associated with traction reflexes, the usual attempts should be made to determine the aetiology of the arrhythmia and the surgical or anesthetic manipulations necessary to correct parasympathetic imbalance should be performed. Adults: In those situations where intraoperative use is indicated, a single dose of 0.2 to 0.4 mg (or 0.004 to 0.005 mg/kg up to a maximum of 0.4 mg) by intravenous injection should be used. This dose may be repeated if necessary. Children (1 month to 12 years of age): In those situations where intraoperative use is indicated, a single dose of 0.004 to 0.008 mg/kg or up to a maximum of 0.2 mg by intravenous injection should be used. This dose may be repeated if necessary. Reversal of Neuromuscular Blockade: Adults: 0.2 mg intravenously per 1 mg neostigmine or the equivalent dose of pyridostigmine. Alternatively, a dose of 0.01-0.015 mg intravenously with 0.05 mg/kg neostigmine or equivalent dose of pyridostigmine. Glycopyrronium may be administered simultaneously from the same syringe with the anticholinesterase; greater cardiovascular stability results from this method of administration. Children (1 month to 12 years of age): 0.01 mg/kg intravenously with 0.05 mg/kg neostigmine or the equivalent dose of pyridostigmine. Glycopyrronium may be administered simultaneously from the same syringe with the anticholinesterase; greater cardiovascular stability results from this method of administration.

Side effects

Side effects of antimuscarinics such as glycopyrronium bromide are basically extensions of the fundamental pharmacological action. These include constipation, transient bradycardia (followed by tachycardia, palpitations and arrhythmias), reduced bronchial secretions, urinary urgency and retention, dilatation of the pupils with loss of accommodation, photophobia, dry mouth, flushing and dryness of the skin. Side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness. The following reported adverse reactions are extensions of glycopyrronium bromide’s fundamental pharmacological actions: Cardiovascular: Tachycardia, ventricular fibrillation, bradycardia, palpitation and arrhythmia, hypertension, hypotension, cardiac arrest, heart block, prolonged QTc interval. Dermatological: Flushing and inhibition of sweating, severe allergic reactions or drug idiosyncrasies including urticaria and other dermal manifestations, pruritus, dry skin. Gastrointestinal: Nausea, vomiting, dry mouth, constipation, taste alterations, including loss of taste. Genitourinary: Urinary hesitancy and retention, impotence. Ocular: Blurred vision due to mydriasis, cycloplegia, photophobia, increased ocular tension. Nervous System: Inhibition of transmission at neuromuscular junction, headache, nervousness, drowsiness, dizziness, seizure, insomnia, some degree of mental confusion, especially in the elderly, hyperexcitability in children. Pregnancy and perinatal: Suppression of lactation. Respiratory System: Respiratory arrest. General: Hyperpyrexia bloated feeling, anaphylaxis/anaphylactoid reaction, and hypersensitivity. Injection site reactions including pruritus, oedema, erythema, pain have been reported rarely.

Precautions and warnings

Antimuscarinics should be used with caution (due to increased risk of side effects) in Down’s syndrome, in children and in the elderly. They should also be used with caution in gastro-esophageal reflux disease, diarrhea, ulcerative colitis, acute myocardial infarction, hypertension, conditions characterized by tachycardia (including hyperthyroidism, cardiac insufficiency, cardiac surgery) because of the increase in heart rate produced by their administration, coronary artery disease and cardiac arrhythmias, pyrexia (due to inhibition of sweating), pregnancy and breast feeding. Because of prolongation of renal elimination, repeated or large doses of glycopyrronium bromide should be avoided in patients with uremia. Large doses of quaternary anticholinergic compounds have been shown to block end plate nicotinic receptors. This should be considered before using glycopyrronium bromide in patients with myasthenia gravis. It is known that the administration of anticholinergic agents during inhalation anesthesia can result in ventricular arrhythmias.

Pregnancy and lactation

Data on the use of glycopyrronium bromide in pregnant women, other than on delivery, are not forthcoming, nor is there documentation concerning excretion in breast milk. Although glycopyrronium bromide does not readily cross the placenta, the injection should only be prescribed to pregnant women when clearly necessary. Caution is advised when considering administration to a lactating mother.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250